Key result
Mycophenolate mofetil shows potential vascular benefits, supporting further evaluation in lupus-associated vascular disease.
Answers are grounded in this paper and cite their sources.
Lupus is proving a fertile ground for research into mechanisms of accelerated atheroma. Often referred to as ‘the new diabetes’, lupus has a relative risk of myocardial infarction way in excess of, for example, other inflammatory diseases such as rheumatoid arthritis. The possible suspects are discussed in this issue of LUPUS, with the antiphospholipid antibody family becoming increasingly important. The observation that mycophenolate mofetil might have therapeutic properties in some models of accelerated vascular disease has thus added impetus to studies of mofetil in lupus and related diseases.
No takes yet. Share an insight, caveat, or question.
Hughes et al. (2006) conducted an editorial in Lupus and cardiovascular disease. Mycophenolate mofetil was evaluated. Mycophenolate mofetil may have therapeutic properties in models of accelerated vascular disease, prompting further studies in lupus.
Synapse has enriched 10 related papers. Consider them for comparative context: